Translational pharmacokinetics: Challenges of an emerging approach to drug development in stroke

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 6, 2011, Pages 681-695

  Greenhalgh, Andrew D ^a   Ogungbenro, Kayode ^b   Rothwell, Nancy J ^b   Galea, James P ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BBB; IL 1Ra; pharmacokinetics; pharmacometrics; stroke; translational

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ALTEPLASE; CARBON 11; DEFEROXAMINE; DISUFENTON SODIUM; ERYTHROPOIETIN; FLUORINE 18; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SOMATOMEDIN; TEMOZOLOMIDE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL (TOPIC); DRUG DETERMINATION; DRUG PENETRATION; DRUG RESEARCH; HUMAN; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; REVIEW; STROKE; TRANSLATIONAL RESEARCH;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; BLOOD-BRAIN BARRIER; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; ENDOVASCULAR PROCEDURES; HUMANS; INFUSIONS, INTRAVENTRICULAR; INFUSIONS, SUBCUTANEOUS; MAGNETIC RESONANCE SPECTROSCOPY; NEUROPROTECTIVE AGENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, INTERLEUKIN-1; STROKE;

EID: 79956088967     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.570259     Document Type: Review

References (112)

1. Meairs S, Wahlgren N, Dirnagl U, et al. Stroke Research Priorities for the Next Decade - A Representative View of the European Scientific Community. Cerebrovasc Dis 2006;22:75-82
2. Huang P, Chen C, Yang Y, et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke. Cerebrovasc Dis 2006;22:423-8 (Pubitemid 44681119)
3. Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007, doi:10.1002/14651858.CD000277.pub3 (Pubitemid 351805454)
4. O'Collins VE, Macleod MR, Donnan GA, et al. 1,026 Experimental treatments in acute stroke. Ann Neurol 2006;59:467-77 (Pubitemid 43358067)
5. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007;205:20-5 (Pubitemid 46621180)
6. Sena E, van der Worp HB, Howells D, et al. How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci 2007;30:433-9 (Pubitemid 47374833)
7. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36 (Pubitemid 34840080)
8. Fisher M. STAIR: enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke 2005;36:1808-13 (Pubitemid 41098783)
9. Ritter JM. Pharmacokinetic(s) matters: stroke treatment et cetera. Br J Clin Pharmacol 2008;65:299-300 (Pubitemid 351316924)
10. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007;61:396-402 (Pubitemid 46878767)
11. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005;5:629-40 (Pubitemid 41113194)
12. Mulcahy NJ, Ross J, Rothwell NJ, et al. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003;140:471-6 (Pubitemid 37330491)
13. Emsley HC, Smith CJ, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93-101 (Pubitemid 36694395)
14. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1366-72 (Pubitemid 41360973)
15. Tadros A, Crocco T, Davis SM, et al. Emergency medical services-based community stroke education: pilot results from a novel approach. Stroke 2009;40:2134-42
16. de la Ossa NP, Sanchez-Ojanguren J, Palomeras E, et al. Influence of the stroke code activation source on the outcome of acute ischemic stroke patients. Neurology 2008;70:1238-43 (Pubitemid 351520963)
17. Gargano JW, Wehner S, Reeves MJ. Do Presenting Symptoms Explain Sex Differences in Emergency Department Delays Among Patients With Acute Stroke? Stroke 2009, doi:10.1161/STROKEAHA.108.543116
18. Berthet C, Lei H, Thevenet J, et al. Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab 2009;29:1780-9
19. Sacco RL, DeRosa JT, Haley EC, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 2001;285:1719-28 (Pubitemid 32259906)
20. Kaya D, Gursoy-Ozdemir Y, Yemisci M, et al. VEGF protects brain against focal ischemia without increasing blood-brain permeability when administered intracerebroventricularly. J Cereb Blood Flow Metab 2005;25:1111-18 (Pubitemid 41710737)
21. Fagan SC, Edwards DJ, Borlongan CV, et al. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-51 (Pubitemid 38333198)
22. Barone FC, Irving EA, Ray AM, et al. SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia. J Pharmacol Exp Ther 2001;296:312-21 (Pubitemid 32112455)
23. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 2011;31:439-47
24. McColl B, Allan S, Rothwell N. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009;158:1049-61
25. Hurst S, Loi C, Brodfuehrer J, et al. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol 2007;3:469-89 (Pubitemid 351324958)
26. Smith WS, Sung G, Saver J, et al. Mechanical Thrombectomy for Acute Ischemic Stroke: final results of the multi MERCI trial. Stroke 2008;39:1205-12 (Pubitemid 351440692)
27. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11 (Pubitemid 28046933)
28. Munoz R, Morell V, Cruz E, et al. Critical Care of Children with Heart Disease [Internet]. Springer London; 2010
29. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74:85-94 (Pubitemid 36776180)
30. Clark SR, McMahon CJ, Gueorguieva I, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 2008;28:387-94 (Pubitemid 351161294)
31. Greenhalgh AD, Galea J, Denes A, et al. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol 2010;160:153-9
32. Galliford JW, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 2005;20:1956-62 (Pubitemid 41222614)
33. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol 2008;7:341-53 (Pubitemid 351380535)
34. Langdon PC, Lee AH, Binns CW. Dysphagia in acute ischaemic stroke: severity, recovery and relationship to stroke subtype. J Clin Neurosci 2007;14:630-4 (Pubitemid 46783490)
35. Crome P, Rizeq M, George S, et al. Drug absorption may be delayed after stroke: results of the paracetamol absorption test. Age Ageing 2001;30:391-3 (Pubitemid 33069594)
36. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001;39:209-28 (Pubitemid 32244129)
37. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
38. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102:3811-16 (Pubitemid 40360709)
39. Fletcher L, Kohli S, Sprague SM, et al. Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J Neurosurg 2009;111:164-70
40. Hanson LR, Roeytenberg A, Martinez PM, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009;330:679-86
41. Harkema JR. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect 1990;85:231-8 (Pubitemid 20315302)
42. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650-61 (Pubitemid 47202487)
43. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-16
44. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53 (Pubitemid 41828930)
45. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25
46. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009;31:497-511
47. de Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703 (Pubitemid 34948192)
48. van de Waterbeemd H, Smith DA, Beaumont K, et al. Property-based design:? optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-33
49. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003;8:927-33 (Pubitemid 37230012)
50. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004;447:653-65 (Pubitemid 38241451)
51. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602 (Pubitemid 41059334)
52. Abbott NJ, Khan EU, Rollinson CMS, et al. Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found. Symp 2002;243:38-47; discussion 47-53, 180-5
53. Hermann DM, Bassetti CL. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci 2007;28:128-34 (Pubitemid 46283592)
54. Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 2006;9:487-8
55. Kilic E, Spudich A, Kilic U, et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008;131:2679-89
56. White BC, Sullivan JM, DeGracia DJ, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 2000;179:1-33
57. Castellanos M, Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007;24:7-15 (Pubitemid 350035847)
58. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004;35:2659-61 (Pubitemid 39458362)
59. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7
60. Rha J, Saver JL. The impact of recanalization on ischemic stroke outcome. A meta-analysis. Stroke 2007, doi:10.1161/01. STR.0000258112.14918.24
61. Latour LL, Kang D, Ezzeddine MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468-77 (Pubitemid 39319336)
62. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007;6:258-68 (Pubitemid 46228081)
63. Batra A, Latour LL, Ruetzler CA, et al. Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab 2010;30:1188-99
64. Chen B, Friedman B, Cheng Q, et al. Severe blood-brain barrier disruption and surrounding tissue injury. Stroke 2009;40:e666-74
65. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38:376-85
66. Huang P, Chen C, Yang Y, et al. Eligibility for Recombinant tissue plasminogen activator in acute ischemic stroke. Cerebrovasc Dis 2006;22:423-8 (Pubitemid 44681119)
67. Pillai DR, Dittmar MS, Baldaranov D, et al. Cerebral ischemia-reperfusion injury in rats[mdash]A 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab 2009;29:1846-55
68. Durukan A, Marinkovic I, Strbian D, et al. Post-ischemic blood-brain barrier leakage in rats: one-week follow-up by MRI. Brain Res 2009;1280:158-65
69. Strbian D, Durukan A, Pitkonen M, et al. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience 2008;153:175-81
70. McColl BW, Rothwell NJ, Allan SM. Systemic Inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci 2008;28:9451-62
71. Vo KD, Santiago F, Lin W, et al. MR Imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol 2003;24:674-9 (Pubitemid 36460739)
72. Vries HED, Kuiper J, Boer AGD, et al. The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 1997;49:143-56
73. Kidwell CS, Latour L, Saver JL, et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008;25:338-43 (Pubitemid 351555857)
74. Farrall AJ, Wardlaw JM. Blood-brain barrier: Ageing and microvascular disease - systematic review and meta-analysis. Neurobiol Aging 2009;30:337-52
75. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007;24:1745-58 (Pubitemid 47206624)
76. Katoh M, Suzuyama N, Takeuchi T, et al. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci 2006;95:2673-83 (Pubitemid 46093174)
77. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007;205:20-5 (Pubitemid 46621180)
78. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004;56:1825-57 (Pubitemid 39307054)
79. Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss 1974;30:44-55
80. Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res 1997;14:267-88 (Pubitemid 27160936)
81. Dahlin AP, Wetterhall M, Caldwell KD, et al. Methodological aspects on microdialysis protein sampling and quantification in biological fluids: an in vitro study on human ventricular CSF. Anal Chem 2010;82:4376-85
82. Helmy A, Carpenter KLH, Skepper JN, et al. Microdialysis of cytokines: methodological considerations, scanning electron microscopy, and determination of relative recovery [Internet]. 2009, [no volume]
83. Liu X, Van Natta K, Yeo H, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 2009;37:787-93
84. Rosso L, Brock CS, Gallo JM, et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009;69:120-7
85. Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (Neurokinin1 Receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-23 (Pubitemid 43208967)
86. Cawthorne C, Prenant C, Smigova A, et al. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [(18)F]-IL1RA and PET imaging in rats [Internet]. Br J Pharmacol 2010, doi:10.1111/j.1476-5381.2010.01068.x
87. Aboagye EO, Price PM, Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 2001;6:293-302 (Pubitemid 32194666)
88. Christensen JD, Yurgelun-Todd DA, Babb SM, et al. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. Brain Res 1999;834:1-5 (Pubitemid 29332003)
89. Schenck JF. Physical interactions of static magnetic fields with living tissues. Prog Biophys Mol Biol 2004;87:185-204
90. Bolo NR, Hode Y, Nedelec J, et al. brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000;23:428-38
91. Lyoo IK, Renshaw PF. Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 2002;51:195-207 (Pubitemid 34142631)
92. Mire-Sluis A, Gaines Das R, Padilla A. WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis and as therapeutic agents. J Immunol Methods 1998;216:103-16 (Pubitemid 28440382)
93. Chirmule N, Oyaizu N, Kalyanaraman VS, et al. Misinterpretation of results of cytokine bioassays. J Immunol Methods 1991;137:141-4
94. De Jongh R, Vranken J, Vundelinckx G, et al. The effects of anticoagulation and processing on assays of il-6, sil-6r, sil-2r and soluble transferrin receptor. Cytokine 1997;9:696-701 (Pubitemid 27399837)
95. Hoffmann JN, Hartl WH, Faist E, et al. Tumor necrosis factor measurement and use of different anticoagulants: Possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes. Inflamm Res 1997;46:342-7 (Pubitemid 27443306)
96. Morgan EH, Peters T. The biosynthesis of rat serum albumin. J Biol Chem 1971;246:3500-7
97. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. Ann Intern Med 2001;135:149-64
98. SAFE Study investigators: effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ 2006;333:1044
99. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1006-12 (Pubitemid 44133261)
100. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999;45:942-56 (Pubitemid 29340529)
101. Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 2005;60:581-3 (Pubitemid 41705376)
102. Balant LP, Gex-Fabry M. Modelling during drug development. Eur J Pharm Biopharm 2000;50:13-26 (Pubitemid 30326686)
103. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003;42:883-908 (Pubitemid 36995260)
104. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991;32:669-70
105. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996;30:81-93 (Pubitemid 26069034)
106. Bellissant E, Sebille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998;35:151-66 (Pubitemid 28379426)
107. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010;88:166-82
108. FDA: Innovation or stagnation: challenge and opportunity on the critical path to new medical products. 2004, [no volume]
109. Barrett JS, Fossler MJ, Cadieu KD, et al. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 2008;48:632-49 (Pubitemid 351503519)
110. Gueorguieva I, Clark SR, McMahon CJ, et al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 2008;65:317-25 (Pubitemid 351316912)
111. Gueorguieva I, Ogungbenro K, Graham G, et al. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Programs Biomed 2007;86:51-61 (Pubitemid 46394511)
112. Denes A, Thornton P, Rothwell N, et al. Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun 2010;24:708-23